Novartis AG ADR
$ 151.97
1.50%
17 Apr - close price
- Market Cap 289,015,366,000 USD
- Current Price $ 151.97
- High / Low $ 152.54 / 150.75
- Stock P/E 20.91
- Book Value 24.18
- EPS 7.16
- Next Earning Report 2026-05-05
- Dividend Per Share $4.67
- Dividend Yield 3.17 %
- Next Dividend Date -
- ROA 0.11 %
- ROE 0.31 %
- 52 Week High 165.43
- 52 Week Low 101.83
About
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Analyst Target Price
$153.26
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-28 | 2025-07-17 | 2025-04-29 | 2025-01-30 | 2024-10-28 | 2024-07-17 | 2024-04-22 | 2024-01-30 | 2023-10-24 | 2023-07-17 | 2023-04-25 |
| Reported EPS | 2.03 | 2.25 | 2.42 | 2.28 | 1.98 | 2.06 | 1.97 | 1.8 | 1.53 | 1.74 | 1.83 | 1.71 |
| Estimated EPS | 2 | 2.31 | 2.37 | 2.17 | 1.76 | 1.93 | 1.86 | 1.68 | 1.66 | 1.74 | 1.76 | 1.53 |
| Surprise | 0.03 | -0.06 | 0.05 | 0.11 | 0.22 | 0.13 | 0.11 | 0.12 | -0.13 | 0 | 0.07 | 0.18 |
| Surprise Percentage | 1.5% | -2.5974% | 2.1097% | 5.0691% | 12.5% | 6.7358% | 5.914% | 7.1429% | -7.8313% | 0% | 3.9773% | 11.7647% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.13 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Apr 2025 | Apr 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-16 | 2025-04-25 | 2024-04-19 | 2023-03-20 | 2022-03-17 | 2021-03-15 | None | None | None | None |
| Amount | $4.772961 | $3.99399 | $3.7395445 | $3.4693612 | $3.3574492 | $3.3783783 | $3.0424917 | $2.865 | $2.977 | $2.717759 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVS
2026-04-17 19:51:52
Voltaren's Swiss-licensed topical gel (CH-Lizenz), managed by Novartis, maintains strong demand for pain relief despite increasing healthcare costs and pricing pressures in Switzerland. The article examines how Novartis's licensing strategy impacts consumer access and stock stability, highlighting Voltaren's market position, competition, and the risks and opportunities for investors. Key factors include regulatory reviews, supply chain vulnerabilities, and potential shifts in Novartis's consumer health portfolio, all while addressing the product's relevance for a global audience, including the U.S. market.
2026-04-15 23:11:38
This article provides access to the book value per share for Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs (BCBA:NVSC) on the Buenos Aires Stock Exchange through TradingView. It directs users to the financial data section for the company.
2026-04-15 10:39:27
The article provides an overview of the earnings and revenue for Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S (FWB:NOT1). It presents sections for EPS and revenue snapshots, including reported and estimated figures for both annual and quarterly periods. The report also lists the next report date, report period, and estimates for EPS and revenue.
2026-04-15 08:39:27
Sixteen brokerages have issued a consensus "Hold" rating for Novartis AG (NYSE:NVS), with an average 12-month target price of $141.20. The company recently reported Q4 EPS of $2.03 and revenue of $13.86 billion, slightly exceeding analyst expectations. Novartis also declared an annual dividend of $4.773, representing a payout ratio of 43.02%.
2026-04-15 02:11:38
Novartis AG, a Swiss pharmaceutical company, is highlighted for its robust pipeline of innovative medicines, particularly in gene therapy, immunology, and oncology, positioning it for long-term growth in the healthcare sector. The company's strategic focus on research and development, combined with a diversified portfolio and global market presence, aims to drive significant returns for investors in the United States and other English-speaking markets. While analysts are cautiously optimistic about its strategic priorities and strong pipeline, potential risks include patent expirations and regulatory challenges.
2026-04-15 02:09:37
Novartis AG, a Swiss pharmaceutical giant, is positioned for growth due to its robust pipeline of breakthrough therapies in areas like gene therapy and immunology, making it a key play for long-term healthcare growth. The company's business model centers on R&D for transformative medicines, supported by a diversified portfolio including innovative drugs, a strong generics business via Sandoz, and a growing focus on radioligand therapies. Novartis' strategic focus on high-science assets, coupled with industry tailwinds like personalized medicine and regulatory support, aims to deliver sustained leadership and value for investors.
